1. Home
  2. Products
  3. Customized ADCs
  4. CD22
  5. Anti-CD22 (clone 10F4v3)-BMPEO-DM1 ADC

Anti-CD22 (clone 10F4v3)-BMPEO-DM1 ADC (CAT#: ADC-W-177)

This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4v3) conjugated via a BMPEO linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • Product Information
  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Antibody clone #
  • 10F4v3
  • Name
  • CD22
  • Alternative Names
  • CD22; CD22 molecule; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2;
  • Target Entrez Gene ID
  • 933
  • Overview
  • CD22, or cluster of differentiation-22, is a molecule belonging to the SIGLEC family of lectins. It is found on the surface of mature B cells and to a lesser extent on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases.
    CD22 is a sugar binding transmembrane protein, which specifically binds sialic acid with an immunoglobulin (Ig) domain located at its N-terminus. The presence of Ig domains makes CD22 a member of the immunoglobulin superfamily. CD22 functions as an inhibitory receptor for B cell receptor (BCR) signaling. It is also involved in the B cell trafficking to Peyer's patches in mice.
  • Overview
  • Anti-CD22 antibody, clone # 10F4v3
  • Clone #
  • 10F4v3
  • Species Reactivity
  • Human
  • Name
  • BMPEO (bis-maleimido-trioxyethylene glycol)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
  • Description
  • Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
    macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-177. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-2526 Anti-CD22 (Inotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-2528 Anti-CD22-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-2533 Anti-CD22 (Pinatuzumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-2525 Anti-CD22 (Inotuzumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-461 Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC AcBut (4-(4-acetylphenoxy)butanoic acid) CalichDMH
CAT# Product Name Linker Payload
ADC-W-154 Anti-MUC16 (clone 3A5)-BMPEO-DM1 ADC BMPEO (bis-maleimido-trioxyethylene glycol) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-170 Anti-CD79b (clone hu2F2.D7)-BMPEO-DM1 ADC BMPEO (bis-maleimido-trioxyethylene glycol) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-151 Anti-ERBB2 (clone hu4D5Fabv8)-BMPEO-DM1 ADC BMPEO (bis-maleimido-trioxyethylene glycol) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-028 Anti-CD79b (clone huMA79b.v28)-BMPEO-DM1 ADC BMPEO (bis-maleimido-trioxyethylene glycol) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-153 Anti-EPHB2 (clone 2H9)-BMPEO-DM1 ADC BMPEO (bis-maleimido-trioxyethylene glycol) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-AA-015 anti-HIgG(Fc)Fab-N-DM1 ADC Noncleavable linkers DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-495 Anti-EGFR (J2898A)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-054 Protein A-MCC-DM1 ADC MCC (Maleimidomethyl cyclohexane-1-carboxylate) DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-008 anti-HIgG(Fc)-N-DM1 ADC Noncleavable linkers DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-031 anti-MIgG(Fc)Fab-N-DM1 ADC Noncleavable linkers DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.